Calcium Disodium EDTA Chelation Suppositories: A Novel Approach for Removing Heavy Metal Toxins in Clinical Practice

Heavy metals accumulate in various tissues and are associated with increases in today’s biggest killers: cardiovascular disease and cancer. Reducing these heavy metals from the body has been a challenge to modern day medicine. With the advent of intravenous EDTA chelation, it was possible to remove heavy metals, but this invasive method of heavy metal removal is burdensome and expensive. This review examines the rectal suppository method of chelating and removing toxic metals from the circulation and deposits in tissue storage sites. In preclinical experiments CaNa2EDTA (Detoxamin) rectal suppositories were compared to intravenous (IV) administration of C14-labeled calcium disodium ethylenediaminetetraacetate (CaNA2EDTA) in order to evaluate the absorption, brain and prostate tissue distribution, and excretion in rats. The absolute bioavailability of CaNa2EDTA in blood following rectal dosing was 36.3% of the IV doses route, which confirmed that rectal dosing is an efficient method for delivering EDTA to tissues. Following IV or rectal dosing of C14 labeled CaNa2EDTA, the ratio of radioactive EDTA in tissues compared to blood, showed negligible brain localization. However, prostate tissues were found to have a mean ratio of 3.69 via the IV and 13.6 for the rectal route. The half-life of IV administration was found to be approximately 1.5 hours whereas the half-life of rectal administration was over 8 hours. The total recovery of C14 EDTA expressed as percent of administered EDTA IV and rectally was a mean of 47.3% and 30.3%, respectively at eight hours. The suppository formulation of CaNa2 EDTA was well absorbed; delivering high levels of EDTA to the tissues, prostate in particular (3.5-fold increase over IV administration). In human subjects, adult men with chronic prostatitis and with benign prostate hyperplasia and/or prostate cancer and prostate calculi were treated in an outpatient setting with tetracycline and EDTA suppositories (Detoxamin) for 90 days, and their symptoms and lab results were analyzed. Using the NIH Chronic Prostatitis Symptom Index, statistically significant post-treatment mean reductions in symptoms and pain were found, along with a significant improvement in mean quality of life. Use of the International Prostate Symptom Score also indicated significant reductions in 5/7 symptom categories and significant reduction of mean overall scores. Analysis of blood and stool post-treatment indicated significant changes in mobilized, secreted cations (cadmium, copper, boron, lead, molybdenum, magnesium, and calcium). The blood cholesterol/high density lipoprotein ratio was also significantly decreased. Use of rectal suppositories has proved to be an innovative, effective and simple approach, saving time and money for the patient, and its efficacy and safety have been validated in pre-clinical and clinical studies.